Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Inclusion Criteria: 1. ≥18 years of age at the time of enrollment; 2. Histologically confirmed diagnosis of PTCL as specified below: * PTCL-NOS * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma, ALK-positive * Anaplastic large cell lymphoma, ALK-negative * Transformed mycosis fungoides 3. Failed or intolerant of at least one prior systemic anticancer therapy; 4. ECOG performance status score of ≤ 2 at study entry; 5. At least one site of disease measurable in two dimensions by computed tomography (CT); 6. Subjects who are positive for CCR4 by immunohistochemistry; 7. Resolution of all clinically significant toxic effects of prior cancer therapy to grade ≤1 (NCI-CTCAE, v.4.0); 8. Adequate hematological hepatic and renal function. Exclusion Criteria: 1. Subject with the following PTCL diagnoses are excluded; * Precursor T/NK neoplasms * Adult T-cell leukemia-lymphoma * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Aggressive NK-cell leukemia * Systemic EBV-positive T-cell lymphoproliferative disorder of childhood * Hydroa vacciniforme-like lymphoma * Mycosis fungoides, other than transformed mycosis fungoides * Sezary Syndrome * Primary cutaneous CD30+ disorders: Anaplastic large cell lymphoma and lymphatoid papulosis * Primary cutaneous CD8+ aggressive epidermotropic cytoxic T-cell lymphoma * Primary cutaneous CD4+ small/medium T-cell lymphoma * Primary cutaneous gamma-delta T-cell lymphoma * Extranodal NK/T T-cell lymphoma-nasal type * Enteropathy-associated T-cell lymphoma * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis -like T-cell lymphoma * Chronic lymphoproliferative disorder of NK cells 2. Have had an invasive solid tumor malignancy in the past five years except non-melanoma skin cancers, melanoma in situ, cervical carcinoma in situ, ductal/lobular carcinoma in situ of the breast, or localized prostate cancer with a current PSA of ≤ 0.1 ng/ml who is currently without evidence of disease; 3. Relapsed less than 75 days of autologous stem cell transplant; 4. History of allogeneic stem cell transplant; 5. Evidence of central nervous system (CNS) metastasis; 6. Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements; 7. Subjects with a history of moderate or severe psoriasis or with psoriasis associated with systemic symptoms e.g. arthropathy), or with a 1st degree relative with history of psoriasis that required medical intervention; 8. Significant uncontrolled intercurrent illness; 9. Known or tests positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C; 10. Active herpes simplex or herpes zoster; 11. Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins; 12. Known active autoimmune disease will be excluded (For example: Grave's disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease); 13. Is pregnant (confirmed by beta human chorionic gonadotrophin \[β-HCG\]) or lactating; Prohibited Therapies and/or Medications 14. Prior treatment with KW-0761; 15. Initiation of treatment with systemic steroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects; 16. Initiation of treatment with topical steroids while on study is not permitted except to treat an acute rash; 17. Have had anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational medications within 4 weeks of screening visit; 18. Subjects on any immunomodulatory drug.